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• Highly effective and safe direct-acting antivirals (DAAs) 
against hepatitis C virus (HCV) combined with U.S. 
Preventive Services Task Force recommendation to screen 
for HCV in individuals born between 1945 and 1965 (age 
cohort; 54-79 years of age in 2019) was expected to 
reduce the number of actively infected patients via 
identification and treatment. 
• However, new infections with Hepatitis C Virus (HCV) 
continue to occur in the United States, with the CDC 
reporting 2.4 million Americans living with HCV in 2018.
• A study of predominantly African American (AA) patients 
in our university medical practice, during the interferon 
era (2002-2003) and prior to the introduction of DAAs 
(2012-2013), confirmed  a population within the age 
cohort for our patients (Rutledge et al, 2017). 
• Data was collected from 2019 HCV patient EMR charts 
including demographics, laboratory studies, Fibrosis 
assessment by FibroScan, and treatment history.                                   
• AST Platelet Ratio Index (APRI= ((AST value /AST upper 
limit)/Platelet Count) x 100), FIB-4 (FIB-4= (Age(years) x 
AST)/(Platelet Count x Sqrt(ALT)), and FibroScan were 
used to determine the degree of liver fibrosis.
• 601 patients with HCV were seen in 2019 and the majority 
were African American (AA) (85%) and male (66%).
1.
OBJECTIVES
• Our aim was to characterize the 2019 patient population 
seen in the same practice to determine the impact of DAA 
therapy on patient profiles and to test the hypothesis of an 
increase in a younger HCV infected population 
• A shift in patient demographics toward younger, 
non-AA patients in the current DAA era was in 
contrast with the age stability of AA patients who 
are still within the screening age cohort.
• The emergence of younger patients has important 
implications for screening, patient outreach, and 
treatment plans. 
• Half of the HCV infected patients were not started 
on any treatment in 2019. Further examination 
found that only 9 AA and 1 non-AA patients were 
subsequently treated through July of 2020. The 
extent to which the COVID-19 pandemic influenced 
these numbers remains to be evaluated.
• Given the younger population and the poor 
treatment rate, one time screening of all patients 
and continued follow-up after initial visit to close the 
linkage to care gap is recommended.
RESULTS (cont.)
There was no racial disparity among AA and Non-AA patients with respect 
to treatment status at time of the first 2019 visit, with 25% having 
achieved a sustained viral load response (SVR)  prior to 2019 and 25% 
starting treatment in 2019 (Table 1).
Age of  HCV Patients in 2019 by Race and Gender
Figure 1. Age by gender was plotted as a function of race. Non-AA HCV 
patients  were younger than AA patients regardless of gender.  In contrast 
to AA patients, Non-AA females were younger than Non-AA males             
(p< 0.001).
Figure 2.  Patients were treated 
by both Gastroenterologists
(GI)  and Infectious Disease 
(Non-GI)  physicians.  Similar 
distribution  of the anti-viral 
agent selection was observed. 
Response rates were greater 
than 95% and not different by 
race or gender.
In contrast to the management of HCV patients in the interferon era 
exclusively by hepatologists, patients in 2019 were seen and treated by 





























Fibrosis in 2019 Patients
Figure 3. Fibrosis was assessed in patients by race using three methods. APRI and
FIB-4 are serum-based assays and FibroScan is a non-invasive ultrasound based
transient elastography procedure. The two groups were patients who had achieved
viral clearance (SVR) prior to assessment of fibrosis and patients who had not yet
been treated for their HCV infections. There was no significant difference between
the two groups, although the majority of SVR patients had not yet reached 2-3
years after successful treatment.Treatment Profiles
MALE (p<0.001) FEMALE (p<0.001)
Ria Minawala1, Paul Naylor PhD2, Murray Ehrinpreis MD2, Milton Mutchnick MD2
1 Wayne State University School of Medicine; 2 Wayne State University School of Medicine, Division of Gastroenterology
